Overview
We have already successfully constructed the plasmid (BBa_K3712015) and engineered an intelligent temperature-controlled and user-friendly expression system to express two small drug molecules BLP-7 and TLR2 antagonist with ELP to achieve in situ response at the lesion ,verifying the feasibility of four molecules expression Wild-type BLP-7-27 ELP(BBa_K3712023), Optimized BLP-7-27 ELP(BBa_K3712018), Wild-type TLR2 antagonist-27ELP (BBa_K3712022), and Optimized TLR2 antagonist-27 ELP(BBa_K3712008).
Basic Parts
| Part name | Type | Description | Length |
|---|---|---|---|
| BBa_K3712000 | Coding | a kind of elastin like peptide (VPGIG)27 | 405 |
| BBa_K3712002 | Coding | Optimized BLP-7 | 99 |
| BBa_K3712003 | Coding | a kind of elastin like peptide (VPGIG)54 | 810 |
| BBa_K3712004 | Coding | a kind of elastin like peptide (VPGIG)16 | 240 |
| BBa_K3712005 | Coding | Wild-type TLR2 antagonist | 363 |
| BBa_K3712006 | Coding | Optimized TLR2 antagonists | 357 |
| BBa_K3712009 | Coding | Wild-type BLP-7-27 ELP | 497 |
| BBa_K3712011 | Coding | Flexible peptide | 15 |
| BBa_K3712012 | RBS | pR/pL RBS | 11 |
| BBa_K3712013 | Regulatory | pR/pL promotor | 244 |
| BBa_K3712014 | Terminator | rrnB terminator | 206 |
| BBa_K3712016 | Coding | Wild-type Bombinin-like peptide 7 (BLP-7) | 81 |
Composite Parts
| Part name | Type | Description | Length |
|---|---|---|---|
| BBa_K3712007 | Composite | Wild-type TLR2 antagonist-27 ELP | 783 |
| BBa_K3712008 | Composite | Optimized TLR2 antagonist-27 ELP | 762 |
| BBa_K3712015 | Plasmid_Backbone | pBV220 plasmid | 3683 |
| BBa_K3712017 | Composite | Wild-type BLP-7-27 ELP | 501 |
| BBa_K3712018 | Composite | Optimized BLP-7-27 ELP | 519 |